Three RP-LC methods have been developed for the quantitative determination of some anticholinergic drugs in the presence of their degradation products and/or in mixture with other drugs. In method (I) pipoxolan HCl is estimated in the presence of its alkaline-induced degradation products, 0.02 M phosphate buffer pH 7.5: acetonitrile (30:70 v/v) was used as a mobile phase with UV detection at 215 nm. Drofenine HCl was used as an internal standard. Method (II) describes the simultaneous determination of drofenine HCl and propyphenazone in the presence of drofenine HCl alkaline-induced degradation product. This method used 0.05 M phosphate buffer pH 3.5: acetonitrile (60:40 v/v) as a mobile phase with UV detection at 215 nm. In method (III) the simultaneous determination of isopropamide iodide and triflouperazine HCl is presented. In this method 0.05 M phosphate buffer (containing 0.1% triethylamine) pH 3.5: acetonitrile (50:50 v/v) was used as a mobile phase with UV detection at 210 nm. Pipoxolan HCl was used as an internal standard in the determination of the two binary mixtures.
INTRODUCTION
Pipoxolan hydrochloride, 5, 5-diphenyl-2-(2-piperidinoethyl)-1, 3-dioxolan-4-one, is a smooth muscle relaxant 1 used in the treatment of spasms and colic due to irritable bowel syndrome. In 2010, it was reported that pipoxolan HCl inhibits the proliferation of HL-60 human leukemia cancer cell 2 . Its dioxolan moiety was thought to induce apoptosis in cancer cells 3 .
Drofenine hydrochloride, 2-(diethylamino)ethyl α-phenylcyclohexaneacetate hydrochloride, is an antimuscarinic drug used in the treatment of visceral spasms 1 . Isopropamide iodide, (3-carbamoyl-3,3diphenylpropyl) di-isopropylmethyl ammonium iodide, is a quaternary ammonium antimuscarinic with peripheral effects similar to those of atropine. It is used as an adjunct in the treatment of peptic ulcer disease, in the relief of gastrointestinal and urinary-tract disorders associated with smooth muscle spasm 1 .
The combination of isopropamide iodide with triflouperazine HCl provides an optimal and rapid relief in painful conditions associated with visceral spasm.
Propyphenazone, 4-isopropyl-2,3dimethyl-1-phenyl-3-pyrazolin-5-one, is a pyrazolone derivative related to phenazone has analgesic and antipyretic properties 1 Triflouperazine hydrochloride, 10-[3-(4methylpiperazin-1-yl)propyl]-2-trifluoromethylphenothiazine dihydrochloride, is a phenothiazine antipsychotic drug causes sedation. It is used for the treatment of schizophrenia and other psychoses and for the control of nausea and vomiting 1 .
There is no literature was reported for the determination of pipoxolan HCl.
Several methods have been reported for the determination of drofenine HCl with allobarbital and aminophenazone by gas chromatography 4 and by LC methods [5] [6] [7] .
Several methods have been reported for the determination of isopropamide iodide with triflouperazine HCl by spectrophotometric methods [8] [9] [10] and with other drugs by LC methods [11] [12] [13] . 
Isopropamide iodide Triflouperazine HCl
Chemical structure of pipoxolan HCl, drofenine HCl, propyphenazone, isopropamide iodide and triflouperazine HCl.
EXPERIMENTAL

Materials
Pipoxolan HCl working standard was kindly supplied by Amoun pharmaceutical Co., Cairo, Egypt. Its purity was found to be 100.33 ± 0.587 (n=6) according to the manufacturer's method 14 . Drofenine HCl and propyphenazone were kindly supplied by Pharco Co., Alex, Egypt. Their purities were found to be 99.84 ± 0.584 and 99.51 ± 0.795 (n=6) according to the manufacturer's method 15 In method (II): 0.05 M phosphate buffer pH 3.5 (prepared by dissolving 6.8 gm potassium dihydrogen orthophosphate in 900 ml distilled water, adjusted to pH 3.5±0.1 with orthophosphoric acid and diluted with distilled water to 1000 ml): acetonitrile (60:40 v/v).
In method (III): 0.05 M phosphate buffer pH 3.5 (prepared by dissolving 6.8 gm potassium dihydrogen orthophosphate in 900 ml distilled water containing 1ml triethylamine and adjusted to pH 3.5± with orthophosphoric acid then diluted with distilled water to 1000 ml): acetonitrile (50:50 v/v).
Preparation of sample Standard solutions
Pipoxolan HCl stock solution (0.1 mg ml -1 ) was prepared by dissolving accurately weighed 10 mg of into 100 ml volumetric flask, and completing to the volume with the diluting solution.
Drofenine HCl stock solution (0.2 mg/ml) and propyphenazone (0.1 mg/ml) were prepared by introducing accurately weighed 20 mg of and 10 mg of into two separate 100 ml volumetric flasks, dissolving and completing to the volume with the diluting solution.
Isopropamide iodide and triflouperazine HCl stock solutions (0.1 mg/ml) each were prepared by dissolving accurately weighed 10 mg of and 10 mg of into two separate 100 ml volumetric flasks, and completing to the volume with the diluting solution.
Degradation product stock solutions
An accurate weight (50 mg) of each of pipoxolan HCl and drofenine HCl was refluxed separately with 25 ml 1N NaOH for 4 hr then neutralize with 1N HCl and completed to 100 ml with water. Accurately measured aliquots of these solutions equivalent to 10 mg of pipoxolan HCl and 20 mg of drofenine HCl were introduced separately into two 100 ml volumetric flasks and completed to the volume with the diluting solution.
Calibration For pipoxolan HCl (method I)
Accurately measured aliquots equivalent to (100-600 μg) of pipoxolan HCl from its stock solution were transferred into a series of 10 ml volumetric flasks. An aliquot equivalent to (50 μg) of drofenine HCl (internal standard) was added to each volumetric flask and the volume was completed with the diluting solvent. A volume 100 µl of each dilution was injected in triplicate; the chromatograms were recorded using 0.02M phosphate buffer pH 7.5: acetonitrile (30:70 v/v) as the mobile phase. The elution was carried out at ambient temperature using UV detection at 215 nm and a flow rate 1.5 ml/min.
For drofenine HCl and propyphenazone (method II)
Accurately measured aliquots equivalent to (200-1400 μg) of drofenine HCl and (100-700 μg) of propyphenazone from their stock solutions were transferred separately into two series of 10 ml volumetric flasks. An aliquot equivalent to (50 μg) of pipoxolan HCl (internal standard) was added to each volumetric flask and the volume was completed with the diluting solvent. A volume 100 µl of each dilution was injected in triplicate; the chromatograms were recorded using 0.05M phosphate buffer pH 3.5: acetonitrile (60:40 v/v) as the mobile phase. The elution was carried out at ambient temperature using UV detection at 215 nm and a flow rate 1.5 ml/min.
For isopropamide iodide and triflouperazine HCl (method III)
Accurately measured aliquots equivalent to (100-600 μg) of isopropamide iodide and (100-600 μg) of triflouperazine HCl from their stock solutions were transferred separately into two series of 10 ml volumetric flasks. An aliquot equivalent to (50 μg) of pipoxolan HCl (internal standard) was added to each volumetric flask and the volume was completed with the diluting solvent. A volume 100 µl of each dilution was injected in triplicate, the chromatograms were recorded using 0.05 M phosphate buffer pH 3.5 (containing 1ml/l triethylamine): acetonitrile (50:50 v/v) as the mobile phase. The elution was carried out at ambient temperature using UV detection at 210 nm and a flow rate 1.5 ml/min.
The ratios (R) of the recorded area under the peak (AUP) of each drug to that of the internal standard were plotted versus the corresponding concentrations in µg/ml to obtain the calibration curve of each drug and the corresponding regression equations were computed.
Assay of laboratory prepared mixtures For pipoxolan HCl
Aliquots from pipoxolan HCl and its alkaline-induced degradation products (1&2) stock solutions equivalent to pipoxolan HCl (0.20 -0.55 mg) and degradation products (1&2) (0.05 -0.40 mg) were transferred into one series of 10 ml volumetric flasks. An aliquot equivalent to (50 μg) of drofenine HCl (internal standard) was added to each flask and the volume was completed with the diluting solution.
For drofenine HCl
Aliquots from drofenine HCl and its alkaline-induced degradation product (3) stock solutions equivalent to drofenine HCl (0.55 -1.25 mg) and degradation product (3) (0.15 -0.85 mg) were transferred into one series of 10 ml volumetric flasks. An aliquot equivalent to (50 μg) of pipoxolan HCl (internal standard) was added to each flask and the volume was completed with the diluting solution.
The chromatographic conditions were applied for each laboratory prepared mixture and the concentrations of each drug in these mixtures were calculated by substituting the regression equation for each drug.
Application to pharmaceutical preparations
Twenty tablets of each of Rowapraxine tablets, Spasmocebalgin tablets and Stellamide tablets were weighed, ground and an accurate weight of the powdered tablets equivalent to (10 mg) pipoxolan HCl in case of Rowapraxine tablets, (20 mg) drofenine HCl in case of Spasmocebalgin tablets and (10 mg) isopropamide iodide in case of Stellamide tablets were introduced separately into 100 ml volumetric flask, 80 ml diluting solution was added and the solution was sonicated for 30 min. The volume was completed with the diluting solution, (0.1 mg/ml) pipoxolan HCl in case of Rowapraxine tablets, (0.2 mg/ml) drofenine HCl in case of Spasmocebalgin tablets and (0.1 mg/ml) isopropamide iodide in case of Stellamide tablets the solutions were filtered and the first 10 ml of the filtrate was rejected.
Each pharmaceutical preparation was analyzed according to instrumental parameter as under linearity.
RESULTS AND DISCUSSION
Pipoxolan HCl containing a dioxolan moiety which is important for its activity 3 so it was necessary to develop simple stability indicating assay method for the determination of pipoxolan HCl in presence of its alkalineinduced degradation products. However, by reviewing the literature concerning the determination of this drug, it was found that no literature was reported for the determination of pipoxolan HCl by LC either alone or with its degradation products. Several mobile phases with different ratios for their components were tried such as: A satisfactory separation was obtained with the mobile phase 0.02 M phosphate buffer pH 7.5 : acetonitrile (30:70 v/v) as it showed good separation of pipoxolan HCl and degradation products (1&2) at retention time for pipoxolan HCl 4.994 min and for degradation products (1&2) 1.815 min and 2.400 min, respectively. Drofenine HCl was chosen as internal standard as it eluted at reasonable retention time 7.046 min and showed good separation from mixture components (Fig. 1) . The formation of two degradation products of much higher polarity than pipoxolan HCl as shown by their retention time [degradation product (1) 1.815, degradation product (2) 2.400 and pipoxolan HCl 4.994 min] could be attributed to the cleavage of the lactone group giving a product with a COOH & OH groups [degradation product (1) 1.815 min]. Decarboxylation of degradation product (1) gives a degradation product containing OH with less polarity than the first [degradation product (2) 2.400 min]. no literature describing the simultaneous determination of these two drugs by LC was found. Drofenine HCl and its degradation product cyclohexane phenyl acetic acid were estimated using spherisorb ODS column and mobile phase containing acetonitrile : 0.02 M sodium acetate buffer solution with 0.59% of di-n-butylamine (65:35 v/v) adjusted to pH 4.5 with acetic acid at a flow rate 1.5 ml/min and detection at 260 nm but poor peak shapes were observed for drofenine HCl and cyclohexane phenyl acetic acid (tailing factor for drofenine HCl= 4.6 and for cyclohexane phenyl acetic acid= 2.42) 7 .
Several mobile phases with different ratios for their components were tried for the separation of drofenine HCl, propyphenazone and degradation product (3) such as: The chosen mobile phase was 0.05 M phosphate buffer pH 3.5: acetonitrile (60:40 v/v) as it showed good separation of drofenine HCl, degradation product (3), pipoxolan HCl and propyphenazone at a flow rate of 1.5 ml/min and UV detection at 215 nm. Retention time for drofenine HCl was 7.010 min, for degradation product (3) was 13.807 min and for propyphenazone was 3.645 min pipoxolan HCl was chosen as internal standard as it eluted at reasonable retention time at 4.564 min and showed good separation from mixture components (Fig. 2) . The chosen mobile phase was 0.05 M phosphate buffer pH 3.5 (containing 1 ml/l triethylamine): acetonitrile (50:50 v/v) as it showed good separation of isopropamide iodide and triflouperazine HCl at a flow rate of 1.5 ml/min and UV detection at 210 nm. Retention time for isopropamide iodide was 3.729 min and for triflouperazine HCl was 7.115 min. Pipoxolan HCl was chosen as internal standard as it eluted at reasonable retention time at 5.709 min and showed good separation from mixture components (Fig. 3) . System suitability tests of LC method shows good resolution for the drugs, (Table 1) .
Isopropamide iodide and triflouperazine
Linear relationship was obtained between the ratios (R) of the recorded area under the peaks of each drug to that of the internal standard. The concentration ranges and the regression equations are displayed in tables 2-4.
The results of assay validation of the proposed methods show that the methods are accurate, precise and specific according to the %RSD of intraday and interday determination, (Tables 2-4) .
A statistical comparison of the results obtained by the proposed methods and reference methods that depends on colorimetric determination of pipoxolan HCl 14 and drofenine HCl 15 , official methods; potentiometric titration of propyphenazone 16 and triflouperazine HCl 16 and non-aqueous titration of isopropamide iodide 17 .The values of the calculated t and F are less than the tabulated ones, which reveals that there is no significant difference with respect to accuracy and precision between the proposed and the reference methods, (Table 5 ). 
Conclusion
The proposed methods enables simple, accurate and reproducible quantitative RP-LC determinations of pipoxolan HCl in presence of its alkaline degradation products, a mixture of drofenine HCl and propyphenazone in presence of drofenine alkaline degradation product and isopropamide iodide and triflouperazine HCl binary mixture.
